Senior Professor - Universitats Klinikum Heidelberg
Neurology
Professor Werner Hacke was Professor and Chairman of the Department of Neurology in Heidelberg from 1987 until 2014 and is nowthe first Senior Professor in Medicine at the Ruprecht Karl´s University Heidelberg, Germany. He graduated in Medicine at the medical school oft he Aachen Technical University (RWTH) and also holds a Masters degree in Psychology. Prof Hacke had a leading role in the development of Neurological Critical Care, acute stroke management and Stroke Unit care, intra-arterial and intravenous thrombolytic therapy and has pioneered hypothermia and decompressive surgery for malignant MCA-infarction. Prof Hacke was the recipient of the Yamanouchi Europe research Award, the first non-US recipient of the „Feinberg Award for excellence in stroke research“, given by the American Stroke Association (1998), and the first recipient of the Karolinska Stroke Award, Stockholm, Sweden in 2004, the WSO Presidents Award in 2008, the Mihara Award (Japan) and the Jarecki Award (USA) both in 2009. In 2013 he was awarded the Wepfer Award by the European stroke conference. In 2018 he received the ESO science award and in 2020 the WSO Leadership in Stroke Award. He was President of the German Neurological Society 2000-2002 and the President of the German Intensive Care Society 2002-2004. He was the founding President of the European Stroke Organization (ESO) and is now its Honorary President. He is Honorary Member of the German Neurological Society, the German Stroke Society, both the German Society of Neurosurgery and the German Society of Neuroradiology, a Honorary Fellow of American Neurological Association (ANA), and a Honorary President of Neurocritical Care Society (NCS). Dr. Hacke is a Member of the Heidelberg Academy of SciencesHe holds honorary doctor degrees given by the State University of Georgia (Tblisi, Georgia) and the University of Debrecen, Hungary. Dr. Hacke was and is involved with many clinical studies, both industry-supported and investigator driven. Recently he lead studies such as ECASS I-IV, AbESTT I and II, DIAS I and II, CHARISMA, DESTINY and DESTINY II, SPACE I and II, ROCKET AF, and others as chair or co-chair of the steering committees. Werner Hacke has published more than 500 articles listed in pubmed. His h-index is 151 (google-scholar citations). With almost 200,000 citations (July 2029) he is one of the most frequently cited Clinical Neurologist worldwide. He was a "highly cited researcher" by Thomson Reuter for several years) including 2018-2020.

Moderator of 3 Sessions

Session Type
Other
Date
Wed, 26.10.2022
Session Time
15:30 - 17:02
Room
Room 331
Session Type
Industry
Date
Fri, 28.10.2022
Session Time
11:45 - 12:15
Room
Summit 2
Session Description
EXCELLENT Review and Real-World Experience with EMBOTRAP™ III Revascularization Device – Supported by Cerenovus.

Session Description:

Data from the EXCELLENT (Embotrap eXtraction and Clot Evaluation and Lesion evaLuation for NeuroThrombectomy) registry analyzing the characteristics of removed blood clots and how they impacted stroke recovery will be presented. The efficacy of the EMBOTRAP™ III Revascularization Device in a real-world setting will be assessed, as well as to explore correlations between patient comorbidities, clot characteristics, revascularization rates, and clinical outcomes. Learn why the EMBOTRAP design allows for excellent results across the whole scope of clot composition.

Presenter of 9 Presentations

Opening by Chairs

Session Type
Plenary Session
Date
Thu, 27.10.2022
Session Time
13:30 - 15:30
Room
Hall 406
Lecture Time
13:30 - 13:32

Angels Awards

Session Type
Plenary Session
Date
Thu, 27.10.2022
Session Time
13:30 - 15:30
Room
Hall 406
Lecture Time
14:12 - 14:22

The History of Thrombolysis From NINDS Trial To Present

Session Type
Acute Stroke Treatment
Date
Fri, 28.10.2022
Session Time
17:15 - 18:45
Room
Summit 2
Lecture Time
17:36 - 17:52

Opening words and EXCELLENT Review

Session Type
Industry
Date
Fri, 28.10.2022
Session Time
11:45 - 12:15
Room
Summit 2
Lecture Time
11:45 - 12:00

Closing by Chairs

Session Type
Other
Date
Wed, 26.10.2022
Session Time
15:30 - 17:02
Room
Room 331
Lecture Time
17:01 - 17:02

Closing by Chairs

Session Type
Plenary Session
Date
Thu, 27.10.2022
Session Time
13:30 - 15:30
Room
Hall 406
Lecture Time
15:29 - 15:30

Future Leaders Certificates

Session Type
Plenary Session
Date
Thu, 27.10.2022
Session Time
13:30 - 15:30
Room
Hall 406
Lecture Time
14:22 - 14:32

Opening by Chairs

Session Type
Other
Date
Wed, 26.10.2022
Session Time
15:30 - 17:02
Room
Room 331
Lecture Time
15:30 - 15:31

FINAL ANGIOGRAPHIC, CLINICAL AND THROMBUS COMPOSITION RESULTS OF THE EXCELLENT REGISTRY

Session Type
Plenary Session
Date
Thu, 27.10.2022
Session Time
13:30 - 15:30
Room
Hall 406
Lecture Time
15:20 - 15:29

Abstract

Background and Aims

EXCELLENT (NCT03685578; Cerenovus) is a large, prospective, international, real-world registry of endovascular clot removal in acute ischemic stroke (AIS) with EmboTrap as the first line mechanical thrombectomy (MT) device, which included collection and analysis of the retrieved thrombus material.

Methods

Between September 2018 and March 2021, 1000 “all-comer” subjects treated per standard of care at each center (with EmboTrap as first line) were enrolled at 36 sites (28US, 6EU, 1UK, 1 Israel). The study employed blind endpoint evaluation, including a core imaging lab and an independent 90-day mRS assessment. Retrieved clot was collected per each MT maneuver from 543 subjects across 26 sites and sent for standardized analysis by independent central labs.

Results

Mean age was 70.0±14.17 years (range 18-102), 51.9% (518/999) subjects were female and 9.8% (98/998) had a pre-stroke mRS 3-5. Baseline NIHSS was 15.6±6.85 (range 0-36); 10.2% (71/696) subjects had a large core (ASPECTS 0-5); 5.0% (49/989) had posterior stroke; 55.2% (528/956) underwent MT ≤6hrs of onset; and 38.0% (380/999) received IV-tPA prior to MT. Key outcomes were first pass eTICI 2c-3=38% (315/827); final 2b-3=94.3% (780/827; median #passes=1); 90-day mRS≤2 or ≤pre-stroke 46.8% (429/916); and 90-day all-cause mortality 19.1% (176/922). In univariate analysis of clot components, high red blood cell and low platelet content were significant predictors of good mRS outcome (p<0.001 and 0.018) and negative predictors of 90-day mortality (p<0.001 and 0.011, respectively).

Conclusions

Final angiographic, clinical and thrombus composition results, along with multivariate analysis of predictors of clinical outcomes, will be presented at the time of the conference.

Hide